PMID- 36249045
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of 
      HER2-positive breast cancer: A systematic review and meta-analysis of randomized 
      controlled trials.
PG  - 894861
LID - 10.3389/fonc.2022.894861 [doi]
LID - 894861
AB  - OBJECTIVE: Although dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab, 
      has shown promising results in patients with HER2-positive breast cancer (BC), it 
      is still unclear whether dual therapy will increase adverse effects (AEs) while 
      ensuring the efficacy compared with trastuzumab monotherapy. We conducted a 
      systematic review and meta-analysis to compare the efficacy and safety of 
      combined therapy with monotherapy. METHODS: A systematic search was performed to 
      identify eligible randomized controlled trials (RCTs) that evaluated the 
      administration of dual anti-HER2 therapy [pertuzumab plus trastuzumab or 
      trastuzumab emtansine (T-DM1)] versus monotherapy (trastuzumab or T-DM1). The 
      primary endpoints were overall survival (OS) and progression-free survival (PFS). 
      RESULTS: Fourteen RCTs (8,378 patients) were identified. Compared to monotherapy, 
      dual therapy significantly improved the OS (HR = 0.77, 95% CI: 0.59-0.99) and PFS 
      (HR = 0.74, 95% CI: 0.63-0.86) in advanced BC. In neoadjuvant therapy, dual 
      blockade has a higher ORR rate than monotherapy. Grade 3 or higher febrile 
      neutropenia, diarrhea, and anemia as well as heart failure were more frequently 
      reported in dual therapy compared to monotherapy. No significant difference in 
      serious AEs was observed between the two groups. In the subgroup analysis, 
      compared to single-target therapy, dual-target therapy has higher OS and PFS 
      rates in Asian patients with advanced therapy; however, total grade >/=3 AEs and 
      serious AEs were significantly higher in the dual group in Asian patients. 
      CONCLUSIONS: Our study confirms that the combination of pertuzumab and 
      trastuzumab therapy could substantially improve the outcome of patients with 
      HER2-positive breast cancer and was well tolerated compared to trastuzumab 
      monotherapy.
CI  - Copyright (c) 2022 Liu, Fang, Li, Li, Qi and Wang.
FAU - Liu, Xiaoyun
AU  - Liu X
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Fang, Yingying
AU  - Fang Y
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Li, Yinjuan
AU  - Li Y
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Qi, Lu
AU  - Qi L
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Wang, Xinghe
AU  - Wang X
AD  - Department of Phase I Clinical Trail Center, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20220928
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9555237
OTO - NOTNLM
OT  - HER2-positive
OT  - breast cancer
OT  - meta-analysis
OT  - pertuzumab
OT  - trastuzumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/01/01
CRDT- 2022/10/17 05:17
PHST- 2022/03/12 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/10/17 05:17 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.894861 [doi]
PST - epublish
SO  - Front Oncol. 2022 Sep 28;12:894861. doi: 10.3389/fonc.2022.894861. eCollection 
      2022.